Abstract Background
Introduction
Determining axillary lymph node status is of critical importance in staging patients with early breast cancer. Even in the era of gene-expression profiling (i.e., microarray), it remains an important independent prognostic marker of disease behavior and ultimate outcome [1, 2] . Furthermore, it plays a role in regional tumor control [3] , which in turn has been shown to contribute to the reduction of breast cancer mortality [4] [5] [6] . Axillary lymph node dissection (ALND) has long been the standard of care for adequate axillary staging. Long-term complications of this treatment, however, are relatively common and include lymphedema, seroma formation, shoulder dysfunction, pain and numbness [7, 8] . As an alternative for ALND sentinel node biopsy (SNB) was introduced some ten years ago with similar staging capacities [9, 10] but with markedly lower morbidity [11] . According to the sentinel lymph node hypotheses, tumor cells migrating from a primary tumor colonize one or a few lymph nodes before involving others. Injection with blue dye and/or radiolabelled colloid around the area of the tumor permits identification of a sentinel node and its status accurately predicts the status of the remaining regional lymphnodes [12] .
Theoretically, the increasing use of SNB as an axillary staging procedure could have led to downstaging as well as upstaging of disease. Due to reported false negative rates of SNB averaging 5% [12] , downstaging might have occurred and ALND and adjuvant systemic treatment might have been omitted unjustly. On the other hand, the elaborate pathologic examination of the sentinel node and the use of more sensitive techniques, such as serial sectioning and immunohistochemistry, have resulted in an easier identification of malignant cells. As a consequence, occult or micrometastases are being detected in 9-23% of originally Hematoxylin&Eosin node-negative cases [13] . These patients will be upstaged to the group of node-positive patients. Despite these uncertainties, most treatment guidelines have endorsed SNB as an alternative to ALND in clinically node-negative patients [14] and most surgeons have adopted the technique as the standard procedure for axillary staging [15] .
The purpose of our study was to investigate whether or not the gradual introduction of the SNB in the Southeast region of The Netherlands has changed the incidence of axillary nodal micrometastases and induced a stage migration on a population based level.
Patients and methods
Patient data were retrieved from the population based Eindhoven Cancer Registry, which records data on all patients newly diagnosed with cancer in the Southeast region of the Netherlands, an area with approximately 2.4 million inhabitants. Collected data were derived from 10 hospitals, consisting of large non-university teaching hospitals and community hospitals, and two radiotherapy departments. Data on patient and tumor characteristics and treatment were collected by the Cancer Registry based on the pathology reports and medical records. The patients were staged according to the Tumor-Node-Metastasis (TNM) system of the International Union Against Cancer (UICC) [16] . Data were continually revised to assure completeness and accuracy [17] .
For this study specifically, data on axillary staging procedure, disease stage and presence of micrometastases were categorized according to year and period of diagnosis, as this shows the increasing implementation of the SNB technique in the area. Sentinel node biopsy followed by axillary lymph node dissection was introduced in the Southeast Netherlands in 1995. In 1997, surgeons started performing SNB procedures as a routine staging procedure and since the year 2000 indications for SNB are being described in national guidelines [18] .
In order to be able to perform a true population-based analysis we included all women diagnosed with primary invasive breast cancer in the period 1994-2005 (n = 17100) and we used characteristics and data of the entire group in the analyses.
Statistical analyses were carried out using SAS (version 9.1 for Windows, SAS institute Inc., Cary, NC). We performed trend analyses for incidence of SNB (with or without concurrent ALND), T-and N-stages. Furthermore we performed logistic regression analyses with both axillary lymph node status (negative vs. positive, including macro-and/or micrometastases) and presence of micrometastases (yes vs. no) as outcome parameters. Three periods were defined to study the trends. Period 1 represents the years 1994-1996 (before introduction of the SNB), period 2 the years 1997-2002 (during implementation of the SNB) and period 3 the years 2003-2005 (after implementation of the SNB). In these models we adjusted for the possible confounding influences of tumor size (defined as T-stage), age at diagnosis and histology. Because of the large fraction of unknown tumor grades in the early years, we left the association between grade and axillary lymph node status out of the analysis. P-values \ 0.05 were considered statistically significant.
Results
Between 1994 and 2005 a total of 17100 patients were treated for primary invasive breast cancer in the Southeast region of The Netherlands. Their characteristics are shown in Table 1 , stratified according to the three pre-defined periods of diagnosis. Age-distribution did not significantly differ in these three periods, but T-stage, N-stage, grade, histology, type of definitive surgery and type of axillary surgery did change significantly. The percentage of patients staged with SNB (with of without following ALND) gradually and significantly increased from 0% in 1994 to 62% in 2005 (Fig. 1) . The percentage of patients with micrometastases increased significantly after introduction of the SNB from 1.0% in 1994 to 4.3% in 2005 (P \ 0.0001), whereas the proportion of patients with positive axillary lymph nodes showed no significant change (Fig. 2) .
To determine the probability of having a positive axillary lymph node status (i.e., micro-and/or macrometastatic disease) in each period, a multivariate logistic regression analysis was performed, adjusting for covariates postoperative tumor size (pT), age at diagnosis and histology ( Table 2 ). The risk of having a positive axillary lymph node status was 14% (95% CI, 1.0-1. Multivariate logistic regression analyses showed that women diagnosed in the period 2003-2005 had a 3.5 (95% CI, 2.5-4.9) times higher risk of having micrometastases compared to women diagnosed in period 1994-1996, adjusted for the effect of covariates pT, age and histology (Table 3 ). In the second model, adjusted for pT, age and histology and also taking into account the method of staging (SNB with or without subsequent ALND vs. ALND), women undergoing SNB were found to have a 4.1 (95% CI, 3.3-5.2) times higher risk of having micrometastases in period 2003-2005 compared to period 1994-1996. Because of the strong association between period and method of staging, the effect of period disappeared when both variables were included in one model simultaneously.
This implicates that the increased possibility of having axillary nodal micrometastases is almost entirely due to introduction of the SNB.
Discussion
After its introduction in the Southeast region of The Netherlands in 1997, the use of SNB as an axillary staging method increased to 62% of the breast cancer patients in 2005. Although the percentage of patients with micrometastases increased significantly from 1.0% in 1994 to 4.3% in 2005, no significant change was observed of the percentage of patients with positive axillary lymph nodes during this period. However, after adjustment for tumor size and age at diagnosis a small but significant increase in the risk of reporting a positive axillary lymph node status could be demonstrated. By using data of the Eindhoven Cancer Registry, we were able to present results based on a large, populationbased and unselected patient population. The patients were treated in both teaching and community hospitals and data thus reflect usual care in The Netherlands. By covering the period 1994-2005, we were able to make a true comparison in time between a period before and after implementation of the sentinel node technique. The introduction of the SNB allowed the application of more time-consuming and costly pathologic examination techniques of serial sectioning, immunohistochemistry and reverse-transferase polymerase chain reaction. Conventional lymph node examination is based on an H&E staining of one or two sections through the largest diameter of the lymph node. The use of serial sections and immunohistochemistry (IHC) has been increasingly advocated in the case of an H&E negative SN in order to detect smaller metastases. Furthermore, molecular methods using reverse transcriptase polymerase chain reaction (RT-PCR) have been used to identify RNA from occult malignant cells in axillary lymphnodes [18] . In The Netherlands the pathology protocol advocated by the EORTC Breast Cancer Group has been adopted by the pathologists and included in the Dutch evidence-based guideline for the treatment of breast cancer. According to this guideline, sentinel nodes should be sliced in at least three sections at 0.25 mm intervals and from each section at least two slides should be made: one for H&E staining and one for IHC [19] . In a prospective study, comparing the risk of axillary node metastases in SNB versus ALND specimens, Giuliano et al. [20] found a 13% higher risk in the group who underwent SNB with multiple sectioning and immunohistochemical staining of sentinel nodes. This excess risk could be explained almost completely by the detection of micrometastases.
A recent study from the Comprehensive Cancer Centre Middle Netherlands showed that the percentage of patients diagnosed with positive lymph nodes increased from 30% in 1997 to 40% in 2002 [21] . This increase could be entirely explained by the increasing proportion of patients with micrometastatic disease, which rose from 1% to 10%. Although the authors concluded that the introduction of SNB led to significant upstaging of breast cancer patients, they only included patients with tumors of 5 cm and smaller and patients diagnosed during the introduction of SNB. In order to determine whether a true stage migration on a population based level occurred, we expanded inclusion criteria to the entire population of breast cancer patients instead of only those with T1 and T2 tumors. Furthermore, we included patients diagnosed over a longer period of time and compared two periods before and after introduction of the SNB. Remarkably, despite the availability of a national guideline regarding SNB, our study showed a smaller increase in number of micrometastases than the report from the central part of The Netherlands [21] . The most likely explanation for this discrepancy is a difference in the thoroughness of the examination of the SN between pathology laboratories, with a varying number of sections and cutting intervals. However, the potential under diagnosis of micrometastatic disease in our region did not result in a survival difference between node-negative breast cancer patients after a SNB without completion ALND or after an ALND [22] . In another recent study a non-significant increase was observed in the proportion of patients with lymph node involvement (32% vs. 27%; P = .16) after SNB implementation, as compared to the period before the implementation [23] . However, in this study, no attempt was made to adjust for changes in tumor size during the study period.
In our study, the increased detection of micrometastases was not accompanied by an increase in the proportion of patients with positive axillary lymph nodes. This could be explained by the effects of the introduction of the breast cancer surveillance program in the same period. This breast cancer screening program promotes bi-annual screening of women for breast cancer with mammography and was first introduced in The Netherlands in 1988 for women between the ages of 50-69 and in 1998 the criteria were expanded to include women between the ages 50-75. Screening is more likely to detect slower growing tumors which could lead to a more favorable stage and grade distribution. After correction for this effect indeed a small but significant stage migration was visible on a population based level.
In conclusion, the introduction of SNB in the Southeast region of The Netherlands has resulted in stage migration, as is reflected by the fourfold increase of the proportion of patients with micrometastases and the small but significant increase of the proportion of patients with positive lymph nodes, after adjustment for the favorable trend in tumor size. The impact on consideration for adjuvant therapy and implications of micrometastatic disease on survival remain uncertain.
